Skip to main content

Day: May 8, 2024

OP Financial Group’s Interim Report for 1 January–31 March 2024: OP Financial Group reports a strong Q1 – operating profit EUR 618 million

OP Financial GroupInterim Report 1 January–31 March 2024Stock Exchange Release 8 May 2024 9.00 am EET OP Financial Group’s Interim Report for 1 January–31 March 2024: OP Financial Group reports a strong Q1 – operating profit EUR 618 millionOperating profit was EUR 618 million (480). Income from customer business, or net interest income, insurance service result and net commissions and fees, increased by 13% to EUR 969 million (857). Net interest income grew by 24% to EUR 763 million (615). Insurance service result decreased by EUR 8 million to EUR –10 million (–2). Net commissions and fees decreased by 11% to EUR 217 million (244). Impairment loss on receivables in the income statement was EUR 39 million (23), accounting for 0.15% (0.09) of the loan and guarantee portfolio. Investment income increased by 19% to EUR 151 million...

Continue reading

First Quarter 2024: Strong growth in US sales of The NGAL Test

May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) — BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announced interim financial results for the first three months of 2024 and business progress for the first quarter of 2024. Financial HighlightsFor the three months ended March 31, 2024:NGAL revenues in the US increased by 80% over the prior year Total revenue of DKK 9.5 million / USD 1.4 million Adjusted EBITDA of DKK (15.3) million / USD (2.2) million Cash and cash equivalents of DKK 45.3 million / USD 6.6 million as of March 31, 2024 (DKK 57.7 million / USD 8.4 million as of March 31,...

Continue reading

Q1 2024 INTERIM REPORT: ON TRACK TO DELIVER ON OUTLOOK

ANNOUNCEMENT NO. 35/2024Q1 2024Revenue up 11% to DKK 7.0bn EBIT reduced 45% to DKK 200m Adjusted free cash flow of DKK -327m CO2 ferry emission intensity lowered 3%OUTLOOK 2024EBIT of DKK 2.0-2.4bn Revenue growth of 8-11% Adjusted free cash flow of around DKK 1.5bn“While we are on track to deliver on our outlook, we continue to focus on improving profit through operational efficiencies across our network,” says Torben Carlsen, CEO.DKK m Q12024Q12023 (Restated) Change, % LTM 2023-24 LTM2022-23 Change, % Full-year 2023 (Restated)               Revenue 7,011 6,341 11 27,975 27,808 1 27,304EBITDA 957 972 -2 4,875 5,105 -5 4,890EBIT 200 363 -45 2,163 2,475 -13 2,326Adjusted free cash flow – 327 258 – 2,188 1,586 – 2,773ROIC, % – – – 6.9 9.2 – 7.6Financial leverage,...

Continue reading

Interim Reports Q1 2024 – Nykredit Realkredit Group

 To Nasdaq Copenhagen A/Sand the press8 May 2024Nykredit today announces its Q1 Interim Reports 2024 of: Nykredit A/S, CVR no 12 71 92 48 Nykredit Realkredit A/S, CVR no 12 71 92 80  Michael Rasmussen, Group Chief Executive, comments on the Q1 Interim Report 2024:Nykredit today presented a profit after tax of DKK 3,544 million, marking our best quarter ever. And this is naturally highly satisfactory. Our good performance was chiefly driven by business and customer growth across the board, even despite the low housing market activity this quarter. Together with our Totalkredit partner banks, we are consequently well placed to support our customers and foster development and growth all over Denmark.Nykredit Bank grew its lending volumes, particularly to corporate clients. Totalkredit increased its mortgage lending to personal...

Continue reading

Sanoma Corporation, Interim Report 1 January–31 March 2024: Improved performance in a seasonally small quarter

Sanoma Corporation, Stock Exchange Release, 8 May 2024 at 8:30 EET Sanoma Corporation, Interim Report 1 January–31 March 2024: Improved performance in a seasonally small quarter This release is a summary of Sanoma’s Interim report 1 January–31 March 2024. The complete report is attached to this release and is also available at www.sanoma.com/en/investors. Q1 2024Net sales amounted to EUR 221 million (2023: 218). Net sales grew in Learning mainly as a result of earlier ordering and were stable in Media Finland. The Group’s organic net sales growth was 5% (2023: 1%). Operational EBIT excl. PPA increased to EUR -24 million (2023: -31) while being seasonally negative. Earnings improved in both Learning and Media Finland. EBIT was EUR -31 million (2023: -43). Items affecting comparability (IACs) were positive and amounted to EUR 2 million...

Continue reading

Bavarian Nordic Announces Interim Results for the First Three Months of 2024

COPENHAGEN, Denmark, May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024.Revenue for the first three months was DKK 831 million, and the operating profit (EBITDA) was DKK 22 million. Revenue from travel health increased by 20% to DKK 447 million and revenue from public preparedness was DKK 344 million, 59% down from first quarter 2023, which is fully in line with expectations after a peak year in 2023 due to the mpox outbreak. Other revenue was DKK 40 million. Financial guidance for the full year is maintained at a revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million.DKK million Q1 2024 Q1 2023 2024 GuidanceRevenue 831 1,252 5,000 – 5,300EBITDA 22 481 1,100 – 1,350Paul Chaplin, President...

Continue reading

NKT A/S Q1 2024 Interim Report: 27% organic growth and investments in Solutions and Applications

Company Announcement 8 May 2024Announcement No. 13 NKT A/S Q1 2024 Interim Report: 27% organic growth and investments in Solutions and Applications NKT CEO Claes Westerlind says: – We have had a successful start to 2024 with continued growth in revenue and operational EBITDA, driven by satisfactory execution and high utilization of existing and expanded capacity. After another significant project award in Q1, NKT’s leading position in the high-voltage market was once again confirmed and our order backlog reached a new record level. To strengthen our position further, we have initiated additional investments in Solutions and Applications, which are expected to be value accretive to shareholders. Financial highlights     EURm Q1 2024 Q1 2023Revenue* 534 422Organic growth 27% 34%Operational EBITDA 75 57Operational...

Continue reading

Prosafe SE: First-quarter results 2024

(Figures in brackets refer to the corresponding period last year) 8 May 2024 – Prosafe SE reported EBITDA of USD 7.2 million (negative USD 6.4 million) for the first quarter of 2024. The year-over-year increase in EBITDA was mainly driven by higher utilisation, with four active vessels during the quarter, compared to two active vessels in the same period of 2023. Operations and HSSEGood operating and safety performance on all vessels Q1 2024 utilisation of 56.3% (28.6%), four out of seven vessels operating during the quarter Safe Zephyrus, Safe Notos and Safe Concordia had 100% utilisation in the quarter; Safe Eurus had 95% utilisation due to minor repairs Four out of six options declared for Safe Concordia taking firm period through 9 November 2024, increasing firm backlog by USD 12.7 million   Backlog of USD 218 million (USD 316...

Continue reading

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024

Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024 Halle (Saale) / Munich, Germany, May 08, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2024 Annual General Meeting will be held on Friday, June 21, 2024 at 01:00 p.m. (CEST) at the Amsterdam offices of NautaDutilh N.V. The full agenda and all relevant documents are available on the Company’s website: https://www.vivoryon.com/2024-annual-general-meeting/. ###         About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines....

Continue reading

Changes in the management of group subsidiaries in Latvia

Mr. Mikus Freimanis, Member of the Management Board of SIA Merks Mājas, Latvian real estate development company belonging to the AS Merko Ehitus group, has announced about his decision to leave the company. Mr. Mikus Freimanis’ term as a Member of the Board of SIA Merks Mājas will end on 22 July 2024. Mr. Mikus Freimanis has worked in different positions in Merko Ehitus group since 2019 and the group is grateful for his contribution to the business development of SIA Merks Mājas. Egija Smila, country head of the group’s Latvian subsidiaries, was appointed as a member of the board of SIA Merks Mājas, with the term of authority beginning on May 15, 2024. Urmas SomelarHead of FinanceAS Merko Ehitus+372 650 1250urmas.somelar@merko.ee AS Merko Ehitus (group.merko.ee) group companies develop real estate and construct buildings and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.